Hantz Financial Services Inc. Takes $839,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,827 shares of the biotechnology company's stock, valued at approximately $839,000.

Several other large investors also recently added to or reduced their stakes in the business. State Street Corp raised its holdings in shares of Ligand Pharmaceuticals by 2.7% in the 3rd quarter. State Street Corp now owns 707,414 shares of the biotechnology company's stock valued at $70,805,000 after acquiring an additional 18,642 shares in the last quarter. Congress Asset Management Co. raised its stake in Ligand Pharmaceuticals by 3.0% in the third quarter. Congress Asset Management Co. now owns 604,038 shares of the biotechnology company's stock valued at $60,458,000 after purchasing an additional 17,414 shares in the last quarter. Chicago Capital LLC lifted its position in Ligand Pharmaceuticals by 6.0% during the third quarter. Chicago Capital LLC now owns 545,821 shares of the biotechnology company's stock valued at $54,631,000 after purchasing an additional 30,875 shares during the last quarter. Geode Capital Management LLC grew its stake in Ligand Pharmaceuticals by 5.5% in the 3rd quarter. Geode Capital Management LLC now owns 428,270 shares of the biotechnology company's stock worth $42,874,000 after buying an additional 22,495 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its holdings in shares of Ligand Pharmaceuticals by 44.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 372,779 shares of the biotechnology company's stock worth $37,312,000 after buying an additional 114,436 shares during the last quarter. Institutional investors own 91.28% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Royal Bank of Canada increased their target price on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an "outperform" rating in a research note on Wednesday, December 11th. Benchmark reiterated a "buy" rating and set a $135.00 price objective on shares of Ligand Pharmaceuticals in a research report on Monday, December 23rd. Barclays boosted their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an "overweight" rating in a research report on Monday, December 16th. Oppenheimer lifted their price target on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ligand Pharmaceuticals has an average rating of "Buy" and a consensus price target of $147.00.

Read Our Latest Research Report on Ligand Pharmaceuticals

Insider Activity at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director John L. Lamattina sold 2,406 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $123.65, for a total transaction of $297,501.90. Following the completion of the transaction, the director now owns 29,515 shares of the company's stock, valued at $3,649,529.75. This represents a 7.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Octavio Espinoza sold 2,104 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $116.37, for a total value of $244,842.48. Following the completion of the sale, the chief financial officer now owns 20,647 shares in the company, valued at approximately $2,402,691.39. This represents a 9.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock opened at $116.55 on Friday. The company has a market capitalization of $2.20 billion, a P/E ratio of 46.43 and a beta of 1.05. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $67.72 and a fifty-two week high of $129.90. The stock has a 50 day moving average price of $115.13 and a two-hundred day moving average price of $109.02.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

Featured Articles

• Five stocks we like better than Ligand Pharmaceuticals
• Consumer Staples Stocks, Explained
• Nebius Group: Market Overreaction or Real AI Disruption?
• Stock Trading Terms - Stock Terms Every Investor Needs to Know
• The Best Way to Invest in Gold Is...
• Buy P&G Now, Before It Sets A New All-Time High
• Why Nike Stock Could Be 2025’s Top Comeback Play

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?

Before you consider Ligand Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.

While Ligand Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here